Results 161 to 170 of about 2,159 (173)

Curing at a Cost: The Zolgensma Revolution

Medicon Medical Sciences
openaire   +1 more source

Lotterie für Zolgensma®: Novartis verlost Mittel gegen spinale Muskelatrophie

Dr. med. Mabuse, 2020
openaire   +1 more source

Recombinant Adeno-Associated Virus Gene Therapy in Light of Luxturna (and Zolgensma and Glybera): Where Are We, and How Did We Get Here?

Annual Review of Virology, 2019
Allison M Keeler, Terence Flotte
exaly  

Note: Zolgensma data manipulation.

The Medical letter on drugs and therapeutics, 2019
openaire   +1 more source

Zolgensma: The multiple and conflicting valuation of advanced therapies for rare diseases

2020
Rabeharisoa, Vololona, Doganova, Liliana
openaire   +1 more source

GKV unter Druck. Hohe Kosten für die Behandlung mit Zolgensma®.

Dr. med. Mabuse, 2020
openaire   +1 more source

Zolgensma - rewolucja w leczeniu rdzeniowego zaniku mięśni (SMA) typu I

2021
Jabłońska, Iwona, Bączyk, Joanna, Słota, Jacek, Goławski, Marcin, Machelski, Grzegorz   +4 more
openaire  

Real-World Safety Data of the Orphan Drug Onasemnogene Abeparvovec (Zolgensma®) for the SMA Rare Disease: A Pharmacovigilance Study Based on the EMA Adverse Event Reporting System

Pharmaceuticals
Annalisa Capuano, Gabriella di Mauro, Nunzia Balzano   +2 more
exaly  

6ER-007 Real-world effectiveness of gene therapy onasemnogene abeparvovec (Zolgensma) for spinal muscular atrophy: a review

2022
exaly  

Molecular frontiers in spinal muscular atrophy: Zolgensma and emerging drug molecules in therapeutic strategies

International Journal of Pharmacy and Pharmaceutical Science
Priyanshu Kalwar, Swati Wakchoure, Pooja Surve, Bhakti Indulkar, Pritee Gole, Chaitali Jaware, Rishabh Jain   +6 more
openaire   +1 more source